Related Experiment Video

Updated: Jun 21, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Characteristics of a novel monoclonal antibody against interleukin-14alpha

Xiaodong Peng1, Changhua Zhou, Dapeng Wei

  • 1Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China.

Hybridoma (2005)
|August 12, 2009
PubMed

Interleukin-14alpha is cytokine encoded by the plus strand of il-14 gene using exons 3-10. It has been demonstrated in an IL-14-transgenic mice model that IL-14alpha could enhance an immune response to both TD and TI antigens and induce a phenotype that is very similar to SLE and Sjögren's syndrome, indicating that IL-14alpha may play an important role in autoimmune disease. To further study the role of IL-14alpha in human immune diseases, there is an urgent need to generate specific anti-human IL-14alpha monoclonal antibodies. In this study, we immunized BALB/c mice with synthesized human IL-14alpha-C polypeptide and obtained a novel monoclonal antibody, the anti-IL-14alpha-C antibody. Analysis by enzyme-linked immunosorbent assay (ELISA), spot-ELISA, Western blot, and immuoprecipitation revealed that the MAb were specifically against recombinant human IL-14alpha protein, and its subtype and affinity constant (K(aff)) were IgG2a/kappa and 1.007 x 10(8) M(-1), respectively. This antibody might facilitate studies for pathophysiology of autoimmune disease.

More Related Videos

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...